Week 10: SARS-CoV-2

4. The spike protein of SARS-CoV-2 is the primary target for _____ development.
8. COVID-19 vaccines work by training the immune system to recognise and combat the _____.
10. _____ is the term used for the time between exposure to the virus and the onset of symptoms.
12. The SARS-CoV-2 virus belongs to the _____ family.
14. Severe cases of COVID-19 can lead to acute respiratory _____ syndrome
16. _____ is the term used for individuals who are infected with the virus but do not show symptoms.
17. _____ is a medication used to treat severe cases of COVID-19 by reducing inflammation.
18. The SARS-CoV-2 genome is made up of _____, which contains genetic instructions for the virus.
19. _____ is the term used for measures taken to prevent the spread of the virus, such as wearing masks and social distancing.

1. SARS-CoV-2 primarily spreads through respiratory _____.
2. The first case of COVID-19 was reported in the city of _____, China, in late 2019.
3. _____ testing is commonly used to diagnose COVID-19.
5. _____ are small airborne particles that can carry the virus and spread it to others.
6. The SARS-CoV-2 virus has a lipid _____, which makes it susceptible to soap and water.
7. The vaccine developed by Pfizer and BioNTech is an ___ vaccine
9. _____ are medications that can help treat COVID-19 symptoms.
11. _____ is the protein on the surface of the virus that binds to the ACE2 receptor on human cells.
13. The process of developing immunity to a virus through vaccination is called _____.
15. SARS-CoV-2 is a _____, single-stranded RNA virus.